The mechanism underlying the mineralocorticoid escape phenomenon remains unknown. To assess the possible contribution of natriuretic peptides to mineralocorticoid escape, rats were injected with 5 mg deoxycorticosterone acetate for 3 d. Plasma atrial natriuretic factor (ANF) rose to twice basal levels and atrial ANF content decreased significantly by 24 h of treatment. This coincided with renal escape and with a significant increase in urinary cGMP excretion. Plasma ANF remained elevated and atrial ANF content continued to decline by 48 and 72 h while atrial ANF mRNA levels increased significantly only at 72 h. Plasma brain natriuretic peptide did not increase during escape although atrial brain natriuretic peptide mRNA levels increased significantly. Chronically administered HS-142-1 (HS), a specific antagonist of the guanylate cyclase-coupled natriuretic peptide receptors, significantly and dose-dependently impaired the escape phenomenon. The highest dose of HS completely suppressed the increase in urinary cGMP. Despite the continued suppression, partial escape was observed by the end of the observation period. HS alone influenced neither plasma nor tissue or urine parameters. These findings show that despite activation of atrial ANF, blockade of the guanylate cyclase-coupled natriuretic peptide receptors impairs the ability of the kidney to escape the Na+ retaining effect of excess mineralocorticoid in a dose-dependent fashion. Later-acting, unknown mechanisms eventually come into play to mediate the escape phenomenon through a guanylate cyclase-independent pathway. Therefore, ANF of cardiac origin appears to be a major factor initiating mineralocorticoid escape through a guanylate cyclase-dependent pathway. (J.
Introduction
Chronic exposure to either endogenous or exogenous mineralocorticoid excess results in a transient period of positive sodium balance that is followed by a brisk natriuresis leading to the normalization of sodium balance despite the fact that the specific effects of mineralocorticoid on sodium transport at the level of the cortical collecting duct (CCD)' are not inhibited (1) . The ability of the kidney to "escape" the continued sodium-retaining effects of mineralocorticoid excess has been the subject of extensive investigation, leading to several mechanistic explanations including increases in systemic arterial pressure (2) , GFR (3), renal perfusion pressure (4) , renal peritubular capillary and interstitial hydrostatic pressure (5) , and renal prostaglandins and kinins (6, 7) , as well as decreases in the levels of angiotensin 11 (8) , renal sympathetic nerve activity (9) , and renomedullary papillary osmolality (10) . However, a significant number of reports have failed to find complete support for many of the above mechanisms (6) (7) (8) (11) (12) (13) (14) (15) (16) and have, therefore, left open the question as to the existence of alternative or complementary mechanisms.
Atrial natriuretic factor (ANF) (17, 18) is a member of the natriuretic peptide family together with brain natriuretic peptide (BNP) ( 19) and C-type natriuretic peptide (20) . ANF markedly increases renal sodium excretion and urinary volume despite an attendant decrease in systemic arterial pressure (17) . Several reports have shown a preceding or coincidental rise in plasma ANF during mineralocorticoid escape, both in animals ( 15, [21] [22] [23] [24] and in humans ( 12, 13, 25 ) . Further, elevated plasma ANF has been found in patients with primary hyperaldosteronism in which congestive heart failure is not part of the syndrome (26). These observations suggest a role for this hormone in mineralocorticoid escape.
BNP is the second member of the family of natriuretic peptides (19) . BNP shares with ANF a spectrum of biological properties (27) . However, little is known about the response of BNP after mineralocorticoid excess, and the role of this peptide in mineralocorticoid escape remains unknown. The third natriuretic peptide, C-type natriuretic peptide, initially thought restricted to the nervous system, is not an effective natriuretic agent (20) .
It is currently accepted that the effects of natriuretic peptides are mainly exerted through cellular events that include the binding of the hormone to specific receptors, activation of two types of membrane particulate guanylate cyclases (GC-A or ANF-A receptor, and GC-B or ANF-B receptor), and elevation of intracellular cGMP levels (28, 29) . In the microdissected nephron segments, mRNA for GC-A receptor has been identified along the various sites (30) . ANF and BNP have a similar potency for cGMP production reflecting the approximately equal binding affinity to the GC-A receptor for these peptides (31, 32) .
The lack of specific antagonists for the guanylate cyclasecoupled natriuretic peptide receptors has been a major impediment in determining the role of natriuretic peptides. Attempts to confirm a participatory role of ANF in the mineralocorticoid escape phenomenon using passive immunization with anti-ANF antiserum have produced conflicting results (22, 33) . However, recently, Morishita et al. (34) isolated the natriuretic peptide receptor antagonist HS-142-1 (HS) from a culture broth of Aureobasidium pullulans melangimum var. By use of affinity crosslinking they demonstrated that HS binds only to the guanylate cyclase-coupled, 135-kD ANF receptor in bovine adrenocortical membrane and not to the 60-kD guanylate cyclasefree clearance receptors in bovine lung membranes (35) . It was also reported that HS selectively inhibits the binding of '"I-ANF to ANF bioactive receptors in the kidney cortex (34) and inhibits ANF-or BNP-induced cGMP production in various cell types in a dose-dependent manner (36) . Furthermore, the effects of ANF and BNP on diuresis and urinary sodium and cGMP excretion in anesthetized rats were significantly reduced by pretreatment with 0.3 mg/kg HS (37 
Plasma and tissue sampling
Trunk blood was collected in ice-chilled tubes containing 1.5 mg/ml EDTA-Na2 and 500 kIU/ml aprotinin. The plasma samples, obtained after centrifugation at 1,500 g for 20 min at 40C, were kept at -80'C until assayed. The hearts were rapidly excised, and the atria and ventricles were dissected. To avoid atrial contamination, ventricular tissue samples were obtained from the apex of the heart. The tissue samples were immediately frozen in liquid nitrogen, and kept at -80'C until peptide or RNA extraction.
Extraction ofplasma and tissue samples
Plasma samples were acidified by adding 100 Ml/ml of 1 N HCl and passed through Sep-Pak C18 cartridges (Millipore-Waters Corp., Milford, MA) that were prewetted with 5 ml of acetonitrile and rinsed with 20 ml of 0.1% trifluoroacetic acid. After plasma processing, the cartridges were washed with 20 ml of 0.1% trifluoroacetic acid (38) , and then eluted with 3 ml of 60% acetonitrile in 0.1% trifluoroacetic acid. Tissue samples were homogenized in 10 vol of an extracting mixture consisting of 0.1 N HCl, 1.0 M acetic acid, and 1% NaCl, and centrifuged at 10,000 g for 30 min at 40C. The supernatants were then extracted using Sep-Pak C18 cartridges as described above for plasma.
Total RNA extraction and Northern blot analysis Atrial and ventricular tissue samples from individual rats (n = 5 for each time point, each group) were extracted using Ultraspec' (Biotecx Laboratories, Houston, TX) according to the manufacturer's directions using a ratio of 100 mg tissue/ml solution. Total RNA from the atria (10 /tg) and ventricle (20 1g) were electrophoretically separated in an agarose-formaldehyde gel, followed by blotting to nylon membranes (Hybond N+, Amersham Corp., Oakville, Ontario, Canada) overnight. PCR cloning of the BNP cDNA, hybridization conditions, and autoradiographic procedures have been described previously (39) . Autoradiographs were scanned using an Ultrascan XL laser densitometer (LKB Produckter, Uppsala, Sweden) and software package (2400 Gelscan XL; LKB Produckter). The scanning values of ANF and BNP mRNAs were normalized by the relative abundance of 28S ribosomal RNA or phosphoglycerate kinase (PGK) mRNA as internal controls to correct for differences in the amount of RNA applied and transfer efficiency.
Assay methods
Concentrations of urinary sodium and potassium were determined in an automatic analyzer (model CX3; Beckman Instruments, Inc., Brea, CA). Urinary cGMP concentrations were determined with a commercially available RIA kit (Dupont-NEN, Boston, MA). Plasma and cardiac tissue concentrations of immunoreactive (ir) ANF and BNP were determined by RIA using anti-rat ANF99-126 and anti-rat BNP64-95 serum, respectively, from Peninsula Laboratories, Inc. (Belmont, CA) (38) . The antibodies used showed less than 0.01% crossreactivity between ANF and BNP.
Statistical analysis
The data were analyzed using ANOVA for repeated measures followed by Fisher's least significant difference test when appropriate. The significance of the difference between pairs of means was determined using an unpaired Student's t test. All results were expressed as mean±SEM and a level of P < 0.05 was considered significant. Results DOCA animals. Plasma irANF in DOCA animals significantly rose from 20±2 fmol/ml at 0 h to 39±5 fmol/ml at 24 h (P < 0.05), and remained significantly elevated at both 48 and 72 h (each P < 0.05, Fig. 1 ). Atrial irANF content significantly decreased below control values (0 h) at 24 h (P < 0.05) and further decreased at 48 and 72 h (P < 0.05 and P < 0.01, respectively; Fig. 2 ). Northern blot analysis with the rat ANF cDNA probe identified a single 0.9 kb mRNA species in the atria (Fig. 3) and ventricle (Fig. 4) . The levels of atrial ANF mRNA began to rise at 24 h and reached statistically higher levels at 72 h (2.4-fold increase at 0 h, P < 0.05; Figs. 3 and 5). In contrast to ANF, irBNP levels did not change in plasma or in atria ( Figs. 1 and 2 ), although atrial BNP mRNA levels increased significantly at 72 h (1.9-fold increase, P < 0.05; Figs. 3 and 5 ). There were no significant changes in ventricular ANF and BNP peptide or specific mRNA levels over the 72 h (Figs. 2, 4 , and 5). Table I and Fig. 6 summarize urinary parameters for DOCAtreated animals. Urinary volume (UV) in DOCA animals was increased over the basal value at 24, 48, and 72 h. The values for the last two time points were statistically significant when compared to basal value. In the same samples, urinary potassium excretion (UKV) increased significantly from the basal value on the first day and remained elevated during the second and third days, thus demonstrating the persistence of the mineralocorticoid action of DOCA. Urinary sodium excretion (UNaV) was decreased markedly as compared to the basal value in the first day, but it returned towards basal levels on the second and subsequent days (1.4±0.2 and 1.8±0.3 1Lmol/g body weight, respectively, Table I , Fig. 6 ), indicating escape from the sodium-retaining effects of DOCA. Urinary cGMP excretion (UCGMPV) was significantly increased over the basal value during the first, second, and third days.
Natriuretic Peptides in Mineralocorticoid Renal Escape
DOCA + HS animals. Plasma irANF in DOCA + HS animals at 72 h tended to be higher compared with those of DOCA animals. Only the rats with DOCA + 0.6 mg/h HS at 72 h had a higher plasma irBNP compared with those at 0 h, but the differences were not statistically significant. Atrial irANF in DOCA + HS animals decreased more markedly, while there was no change in atrial irBNP, as compared to those at 0 h (Fig. 2) . Atrial ANF and BNP mRNA levels in DOCA + HS animals tended to be higher at 72 h than those in animals treated with DOCA alone. However, ventricular ANF and BNP peptide and mRNA levels in DOCA + HS animals were comparable to those of 0 h.
Urinary parameters in DOCA + HS animals are summarized in Table I (21) reported that plasma ANF concentration and atrial mRNA changed in parallel as early as 12 h after 10-mg DOCA injection in rats. In the present work, in which a smaller DOCA dose was used, atrial ANF mRNA levels increased comparatively more gradually and were significantly different from controls only at 72 h. Assuming that ANF mRNA turnover rates are similar between our treated and control animals, the data suggest that atrial ANF gene transcription enhancement is secondarily rather than primarily related to DOCA treatment. This view is further substantiated by the fact that DOCA does not directly stimulate ANF gene transcription in 1 2 3 4 5 6 7 8 9 IWlfX-"" 28S AF. 0.9 kb--+$#00 1 ANF 0.9 kbcultured atrial cardiocytes (41) . Moreover, no specific receptors for mineralocorticoid exist in the cardiac cytosol (42) .
The effects of mineralocorticoid on cardiac release and synthesis of BNP have not been as extensively investigated as those on ANF. The unchanged levels of circulating BNP found in this work does not support a substantial role for this hormone in DOCA escape. However, we found that atrial BNP stores, in a fashion similar to ANF stores, tended to decrease and that BNP mRNA levels, as for ANF mRNA levels, significantly increased after 72 h following DOCA injection. These changes tended to be more pronounced after treatment with HS, possibly reflecting a more pronounced extracellular volume expansion due to a larger suppressive effect on the diuretic and natriuretic activities of natriuretic peptides. These results further suggest that stimulation of BNP secretion and gene transcription in atria are secondary to hemodynamic overload, as indicated for ANF. BNP is co-stored with ANF in a subset of atrial secretory granules (43) and the release mechanisms seem to be, at least in part, via a regulated pathway because atrial BNP secretion is increased in response to appropriate secretagogues such as endothelin-l or phorbol ester (39, 44) . Overall, these findings indicate that atrial BNP can respond to atrial hemodynamic overload induced by DOCA administration. However, the increase in plasma BNP was comparatively small and, unlike ANF, did not reach statistically significant levels over the 72-h period of DOCA administration. The distinctive responsive patterns of plasma ANF and BNP during DOCA administration may reflect differences in their primary site of expression within the heart or differences in pathways for induction of stimulated secretion. Recent evidence suggests that BNP is mainly synthesized and secreted by ventricular cardiocytes in both physiological and pathological conditions (45, 46) . The plasma BNP response is reported to be relatively more pronounced than ANF in patients with essential hypertension in proportion to left ventricular hypertrophy (47) and in patients with congestive heart failure in proportion to ventricular volume overload (45) . These changes in BNP release over a chronic period of demand are in contrast with changes induced by acute maneuvers such as changes in posture or acute intravenous saline infusion, both of which alter atrial pressure and plasma ANF while plasma BNP is unaffected (48, 49) . These results suggest the plasma BNP levels reflect the secretion from ventricle and thus, not atrial but ventricular load or wall tension may be more significant in influencing plasma BNP levels. In the present study we did not observe an increase in ventricular BNP peptide and mRNA levels during DOCA treatment suggesting that ventricular BNP biosynthesis was not significantly stimulated. Absence of ventricular BNP activation may be explained by the insignificant change in arterial blood pressure, and therefore, of left ventricular wall tension, during mineralocorticoid escape (12) (13) (14) . It was noted in the present work that the highest plasma and ventricular BNP and specific mRNA levels were observed in rats treated with DOCA together with 0.6 mg/h HS. Hirata et al. (50) reported that bolus injection of 8 mg/kg HS significantly elevated blood pressure by 8% together with a 14% increase in systemic vascular resistance in DOCA-salt rats. Therefore in our studies, the volume overload and increase in arterial pressure following chronic treatment with the highest dose of HS might have enhanced left ventricular load and wall tension and thus activated BNP synthesis and secretion from the ventricles. While this might have happened, the changes observed were not statistically significant compared with basal (0 h) values. This is in accordance with previous findings showing that plasma BNP levels increase only after the establishment of hypertension in spontaneously hypertensive rats (51) or DOCAsalt hypertensive rats (52) and suggest that more sustained or stronger hemodynamic stimuli may be needed to activate ventricular BNP.
Plasma ANF levels increased to approximately twice the 58) and powerfully increases Na+ -K+ -ATPase activity (59) before and after DOCA-treatment ( 1 ) , showing that the nephron site responsible for escape is different from the mineralocorticoid site of action. The mineralocorticoid action causes an increase in extracellular fluid leading to an increase in GFR and filtered sodium load. In addition, the increase in renal perfusion pressure and decrease in renal sympathetic nerve activity lead to decreased renin release, thereby decreasing the generation of angiotensin H and sodium reabsorption by the proximal tubule (3, 8, 14, 60) . The increase in vasa recta and interstitial hydrostatic pressure due to volume expansion reduce collecting tubular sodium reabsorption by decreasing the hydraulic gradient (5, 61) . ANF should be expected to contribute to these mechanisms by virtue of its property of increasing GFR and directly inhibiting renin release (62, 63) , as well as increasing vasa recta blood flow as a consequence of renal vasodilation (64) . Lastly, ANF binds to the inner medullary collecting duct cells and powerfully stimulates intracellular cGMP production and blocks amiloride-sensitive Na' channels (65) (66) (67) (68) (69) . Overall, the data suggest that ANF contributes to mineralocorticoid escape through combined renal hemodynamic and tubular effects. It is not known at present whether the number and/or affinity of renal natriuretic peptide receptor are increased during mineralocorticoid escape. Studies comparing the effects of exogenously administered ANF before and after fludrocortisone escape in humans (13) showed that enhanced natriuretic effects were observed after escape with a greater suppression of proximal and distal tubular sodium reabsorption. These authors suggest that mineralocorticoid escape is accompanied by a potentiation of the natriuretic effect of ANF.
In summary, we found that plasma ANF increases in association with increases in UV, UNaV, and UCGMPV following sodium retention induced by DOCA excess. The increase in plasma ANF reflects increases in secretion and synthesis of ANF from atria that are probably secondary to central volume overload. Atrial BNP also seems to be stimulated but plasma BNP levels remained comparatively unaffected probably because of a lack of ventricular stimulation. Blockade of guanylate cyclase-mediated natriuretic peptides activities with HS significantly and dose-dependently suppressed the increase in UV, UNaV, and UCGMPV observed during DOCA escape in conscious rats. These results provide new evidence that cardiac ANF plays a significant role in mediating mineralocorticoid escape and that this mediation takes place through a guanylate cyclase-dependent pathway. However, noteworthy is the fact that the highest dose of HS blocked the increase in UCGMPV completely but UNaV in the second and third days tended to increase. This slight but definite increase raises the possibility that cGMP-independent pathways may come eventually into play to restore sodium balance. Whether these pathways lead to complete restoration of sodium balance even with natriuretic peptide guanylate cyclase-coupled receptor blockade remains to be determined.
